Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Deep Phenotyping Gait Deficits in Orthopedic Manifestations of Pediatric Cancer Patients

NCT: NCT07502885 · RECRUITING

NCT IDNCT07502885
StatusRECRUITING
Start Date2026-05
Completion2032-01

Brief Summary

The goal of DEEPGAIT study is to determine how serious walking problems are for pediatric cancer patients who have had orthopedic surgery, how they change over time, and what can be done to help. Healthy participants without cancer will also be included in this study in order to better understand the difference in walking problems between the 2 groups. DEEPGAIT is a long term study that uses advanced tools-including 3D motion capture, muscle sensors, force plates, and wearable devices-to take a detailed look at how these patients move. Their results are compared to healthy children of the same age and sex. PRIMARY OBJECTIVES * Characterize gait deficits in pediatric cancer patients 1 year following orthopedic surgery for lower limb bone sarcoma, soft tissue sarcoma, or steroid-induced avascular necrosis. * Identify personal, disease, treatment and environment risk factors for gait deficits in pediatric cancer patients 1 year following orthopedic surgery for lower limb bone sarcoma, soft tissue sarcoma, or steroid-induced avascular necrosis. SECONDARY OBJECTIVES * Build a library of broadly representative normative reference values to generate age- and sex-matched z-scores to quantify frequency, severity and progression of gait deficits among pediatric cancer patients in relation to healthy controls. * Characterize the changes of gait parameters in pediatric cancer patients with or without gait deficits 1 year after orthopedic surgery for lower limb bone sarcoma, soft tissue sarcoma, or steroid-induced avascular necrosis, up to 5 years after surgery. * Identify personal, disease, treatment and environment risk factors for trajectories of gait deficits in pediatric cancer patients with or without gait deficits 1 year after orthopedic surgery for lower limb bone sarcoma, soft tissue sarcoma, or steroid-induced avascular necrosis, up to 5 years after surgery.

Frequently Asked Questions

What is Deep Phenotyping Gait Deficits in Orthopedic Manifestations of Pediatric Cancer Patients?

Deep Phenotyping Gait Deficits in Orthopedic Manifestations of Pediatric Cancer Patients is a clinical trial registered under NCT07502885. Current status: RECRUITING.

What is the status of NCT07502885?

The current status of NCT07502885 (Deep Phenotyping Gait Deficits in Orthopedic Manifestations of Pediatric Cancer Patients) is: RECRUITING.

When did Deep Phenotyping Gait Deficits in Orthopedic Manifestations of Pediatric Cancer Patients start?

Deep Phenotyping Gait Deficits in Orthopedic Manifestations of Pediatric Cancer Patients started on 2026-05.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.